Please login to the form below

Not currently logged in
Email:
Password:

Cushing's disease

This page shows the latest Cushing's disease news and features for those working in and with pharma, biotech and healthcare.

FDA approves Recordati’s Cushing disease drug Isturisa

FDA approves Recordati’s Cushing disease drug Isturisa

Important new treatment option for patients with rare disorder. Italy’s Recordati has claimed FDA approval for Isturisa, an oral drug for adult Cushing’s disease patients who can’t be ... Cushing’s disease is a rare disorder that occurs when the

Latest news

  • Novartis' acromegaly therapy cleared by FDA Novartis' acromegaly therapy cleared by FDA

    It leads to an increase in bone size, particularly those in the hands, feet and face, alongside other complications such as diabetes, arthritis, kidney disease and cancer. ... A short-acting formulation of Signifor that requires twice-daily dosing is

  • Novartis gets EU nod for rare disease drug Signifor Novartis gets EU nod for rare disease drug Signifor

    Signifor (pasireotide) was first approved in Europe in 2012 as a twice-daily subcutaneous injection for Cushing's disease, but the new depot formulation - called Signifor LAR - requires just one intramuscular ... It is also testing the new formulation

  • Novartis plans filings for acromegaly candidate Novartis plans filings for acromegaly candidate

    A twice-daily formulation of Signifor (pasireotide) is already on the market for the treatment of Cushing's disease, but the latest study assessed a once-monthly intramuscular formulation - called Signifor ... The company has already filed for approval

  • Novartis cancer chief Hoppenot leaves for top job at Incyte Novartis cancer chief Hoppenot leaves for top job at Incyte

    During his time at the helm of Novartis' cancer division Hoppenot presided over the launch of two new cancer therapies, Jakavi for myelofibrosis in 2011 and Signifor (pasireotide) for Cushing's ... disease in 2012, while rolling out new indications for

  • Novartis provides multimedia support to Rare Diseases Day Novartis provides multimedia support to Rare Diseases Day

    The initiative includes fact sheets, infographics and advice on diseases such as  Cushing's disease, gastrointestinal stromal tumor (GIST), chronic myeloid leukemia etc. ... In addition, a 'Rare Diseases Hour' has been incorporated into Novartis'

More from news
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    GSK's current and future oncology R&D pipeline becoming its preferred commercialisation partner. ... Jakavi (rare bone marrow disorder); Signifor (Cushing's disease) plus 16 products in 24 pivotal trials. .

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
The concordance conundrum: creating space for open dialogue
Growing numbers of patients want a partnership model with their HCP, whereby both parties are equally involved in the decision-making process. This model has been linked with an increase in...
Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...

Infographics